A detailed history of Prudential Financial Inc transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Prudential Financial Inc holds 59,115 shares of DSGN stock, worth $369,468. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,115
Previous 63,215 6.49%
Holding current value
$369,468
Previous $211,000 50.71%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.19 - $5.88 $13,079 - $24,108
-4,100 Reduced 6.49%
59,115 $318,000
Q2 2024

Aug 13, 2024

BUY
$3.23 - $4.77 $52,972 - $78,228
16,400 Added 35.03%
63,215 $211,000
Q1 2024

May 14, 2024

BUY
$2.27 - $4.03 $64,468 - $114,452
28,400 Added 154.22%
46,815 $188,000
Q3 2023

Nov 13, 2023

SELL
$2.05 - $8.14 $15,989 - $63,492
-7,800 Reduced 29.75%
18,415 $43,000
Q2 2023

Aug 11, 2023

BUY
$4.99 - $7.64 $130,812 - $200,282
26,215 New
26,215 $165,000

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $349M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.